优化心脏氨基粉症的药物治疗方法
Mohamed Younis1, Ikechukwu Ogbu1, Dinesh K Kalra1
1Division of Cardiology, University of Louisville Hospital, Louisville, KY, United States of America.
Pharmacology & therapeutics
|November 25, 2024
概括
心脏 Amyloidosis (CA) 治疗正在改善,新的疗法用于 transthyretin (ATTR-CA) 和轻链 (AL-CA) 形式. 早期诊断和多学科护理提高了患者的治疗结果和生存率.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心脏粉症 (CA) 是一种具有挑战性的透性心肌病,在历史上预后不佳.
- 以前,有限的治疗选择导致了不良结果.
- 最近的进展通过早期诊断和新的治疗策略提供了希望.
研究的目的:
- 审查当前对心脏氨基粉症 (ATTR-CA) 和轻链心脏氨基粉症 (AL-CA) 的治疗进展.
- 突出针对粉样纤维素形成和生产的新兴疗法.
- 强调多学科护理在管理CA方面的重要性.
主要方法:
- 对ATTR-CA和AL-CA的最新治疗进展的审查.
- 讨论药物类别,包括跨甲基素稳定剂,基因沉默剂和ATTR-CA的单克隆抗体.
- 对AL-CA的化疗策略的概述.
主要成果:
- ATTR-CA疗法旨在抑制粉样纤维素的形成,显示出改善结果的潜力.
- 塔法米迪斯目前是FDA批准的ATTR-CA的唯一药物,预计很快会有更多的药物.
- 治疗AL-CA的重点是化疗,以减少氨基原蛋白的产生.
结论:
- 在CA管理方面取得的重大进展提供了更好的预后.
- 治疗的有效性在很大程度上取决于心脏参与的程度.
- 合作,多学科的护理对于最佳的患者管理至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
386
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
386
Heart Failure Drugs: Inotropic Agents
521
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
521
Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
Heart Failure Drugs: Diuretics
343
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
343
Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316


